Literature DB >> 10770753

Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

S Perea1, G J Pennick, A Modak, A W Fothergill, D A Sutton, D J Sheehan, M G Rinaldi.   

Abstract

A new selective high-performance liquid chromatography (HPLC) method with UV detection for the determination of the investigational triazole voriconazole in human plasma by using acetonitrile precipitation followed by reverse-phase HPLC on a C(18) column was compared with a simple agar well diffusion bioassay method with Candida kefyr ATCC 46764 as the assay organism. Pooled plasma was used to prepare standard and control samples for both methods. The results of analyses with spiked serum samples (run as unknowns) were concordant by the bioassay and HPLC methods, with expected values being obtained. HPLC demonstrated an improved precision (3.47 versus 12.12%) and accuracy (0.81 versus 1.28%) compared to those of the bioassay method. The range of linearity obtained by both methods (from 0.2 to 10 microg/ml for HPLC and from 0.25 to 20 microg/ml for the bioassay) includes the range of concentrations of voriconazole (from 1.2 to 4.7 microg/ml) which are considered clinically relevant. Although either methodology could be used for the monitoring of patient therapy, the smaller variability observed with HPLC compared to that observed with the bioassay favors the use of HPLC for pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770753      PMCID: PMC89846          DOI: 10.1128/AAC.44.5.1209-1213.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Quality control in the determination of cortisol in plasma/serum by using, on every sample, two different three-step separation methods including ultrafiltration, restricted-access high-performance liquid chromatography and reversed-phase high-performance liquid chromatography, and contrasting results to immunoassays.

Authors:  H W Mueller; J Eitel
Journal:  J Chromatogr B Biomed Appl       Date:  1996-04-12

2.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

3.  Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.

Authors:  D George; P Miniter; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection.

Authors:  M Ruhnke; A Schmidt-Westhausen; M Trautmann
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.

Authors:  M Murphy; E M Bernard; T Ishimaru; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

6.  Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.

Authors:  M H Nguyen; C Y Yu
Journal:  J Antimicrob Chemother       Date:  1998-08       Impact factor: 5.790

7.  Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs.

Authors:  M V Martin; J Yates; C A Hitchcock
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

8.  Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery.

Authors:  D Caillot; O Casasnovas; A Bernard; J F Couaillier; C Durand; B Cuisenier; E Solary; F Piard; T Petrella; A Bonnin; G Couillault; M Dumas; H Guy
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

9.  In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.

Authors:  A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations.

Authors:  J S Hostetler; J Heykants; K V Clemons; R Woestenborghs; L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

View more
  24 in total

1.  Development and validation of a high-performance liquid chromatography assay for voriconazole.

Authors:  Gennethel J Pennick; Martin Clark; Deanna A Sutton; Michael G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Joseph Meletiadis; Rafal Al-Saigh; Aristea Velegraki; Thomas J Walsh; Emmanuel Roilides; Loukia Zerva
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

3.  Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum.

Authors:  GholamAli Khoschsorur; Franz Fruehwirth; Sieglinde Zelzer
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.

Authors:  Kathrin Kahle; Peter Langmann; Diana Schirmer; Ulrike Lenker; Daniela Keller; Annegret Helle; Hartwig Klinker; Werner J Heinz
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

5.  Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.

Authors:  Dimitrios Zonios; Hiroshi Yamazaki; Norie Murayama; Ven Natarajan; Tara Palmore; Richard Childs; Jeff Skinner; John E Bennett
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

6.  Determination of voriconazole serum concentration by bioassay, a valid method for therapeutic drug monitoring for clinical laboratories.

Authors:  Emilio Cendejas-Bueno; Manuel Cuenca-Estrella; Alicia Gomez-Lopez
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

7.  Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole.

Authors:  Eric Nulens; Cathrien Eggink; Antonius J M M Rijs; Pieter Wesseling; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

8.  In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.

Authors:  W A Craig; D R Andes
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

9.  Validated LC Method for the Estimation of Voriconazole in Bulk and Formulation.

Authors:  C N Patel; J B Dave; J V Patel; B Panigrahi
Journal:  Indian J Pharm Sci       Date:  2009-11       Impact factor: 0.975

Review 10.  Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.

Authors:  Rajendra S Kadam; Johannes N Van Den Anker
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.